与开发制药业的“下一个大事件”的可能性相比，或者与以低成本成产高价值成分的可能性相比，监管者斤斤计较于这种可能性极低的事件是极不合理的。
When you weigh this against the possibility of the development of the drug industry’s Next Big Thing or, at the very least, a new method to produce high-value compounds at low cost, regulators’ preoccupation with such unlikely events appears to be misplaced.